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MicroRNAs (miRs) played important roles in the cell proliferation, apoptosis and other biological pro-
cesses in cancer. In the present study we found that miR-375 was signiﬁcantly down-regulated in human
papillary thyroid carcinoma (PTC) tissues and cell lines. In this study we try to investigate the biological
activity of miR-375 in human PTC cells and try to ﬁnd the potential target of miR-375. Our study indi-
cated that over-expression of miR-375 could inhibit the PTC cells proliferation and this inhibition was
caused by the induction of cell apoptosis. In vivo animal study indicated that over-expression of miR-375
could signiﬁcantly decrease the migration and invasion of human PTC cell in vivo. These results exhibit
over-expression of miR-375 in human PTC cells could inhibit the process of human PTC. Further study
demonstrated ERBB2 was a direct target of miR-375, over-expression of miR-375 decrease the both
mRNA and protein expression of ERBB2 in human PTC cells. These data indicate miR-375 play important
roles in the process and development of human PTC. These ﬁnds suggested that appropriate application
of miR-375 regulation might be a new sight for the treatment of human PTC in the future.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
MicroRNAs (miRs) are a series of small noncoding RNAs. MiRs
constitute about three percent of the whole genome. About ninety
percent genes could be regulated by miRs. MiRs could regulate the
target genes through binding to the target genes' 30-UTR (1, 2). They
play important roles in the cell proliferation, apoptosis and other
biological processes. Previous studies indicated that some miRs
were abnormal expressed in tumor tissues and tumor cells
including cell lines and primary cells. These genes regulated by the
abnormal expressed miRs usually were oncogenes or tumor sup-
pressor genes (3, 4), so the regulation of miRs might be a way to
regulate tumor progress.ianxi District, Luoyang City,
g).
rmacological Society.
. Production and hosting by ElseThyroid cancer was formed from follicular or parafollicular
thyroid cells, these two type cells could cause papillary or follicular
cancers and anaplastic thyroid cancer (5). Eighty percent of the
thyroid cancers were papillary thyroid carcinoma (PTC) and it was
the most quickly increasing cancer in cancer patients (6). The
present clinical treatment of PTC was surgical removal and radio-
active iodine ablation, sometimes chemotherapy and radiotherapy
also used in the treatment of PTC follow the initial surgical treat-
ment. In order to ﬁnd better therapeutic strategies to cure PTC,
more understanding about the biological mechanism involved in
PTC is becoming more and more important.
Previous studies indicated that miRs may play important roles
in the pathogenesis of human PTC. Pallante et al reported that
miR-221, -222 and -181b were up-regulated in human PTCs (7).
Zhang et al reported that miR-21 was overexpressed in human
PTCs, decrease the expression of miR-21 could inhibit the human
PTC cells proliferation, invasion and induced the apoptosis
through the regulation of programmed cell death 4 (8). He et al
reported that miR-221, -222, and -146 were the 3 most up-
regulated microRNAs in human PTC while miR-219, -138, -345vier B.V. This is an open access article under the CC BY-NC-ND license (http://
X.-Z. Wang et al. / Journal of Pharmacological Sciences 130 (2016) 78e84 79and -26a were down-regulated in human PTCs (9). There was no
report about the biological effects of miR-375 on human PTC,
although it was found to be regulated in other tumors (10). In the
present study we identiﬁed that the miR-375 was abnormal
expressed in human PTCs, we hypothesize that the expression of
miR-375 was associated the biological functions of human PTCs. In
this study we try to investigate the biological effect of miR-375 on
human PTC cells.2. Materials and methods
2.1. PTC tissue samples
Patients were selected from The 1st Afﬁliated Hospital of Henan
University of Science and Technology, 60 pairs of PTC and
noncancerous normal tissue samples were surgically obtained from
these PTC patients. These PTC tissues were diagnosed by an expe-
rienced pathologist. And these patients did not receive any other
treatments before. Samples were stored at 80 C until the further
study.2.2. Animal
BALB/c nude mice (4e6 weeks) were purchased from Shanghai
Laboratory Animal Center (SLAC) and maintained under speciﬁc
pathogen free (SPF) conditions. All animal studies were in accor-
dance with the Guide for the Care and Use of Laboratory Animals;
all animal studies were performed according to the institutional
ethical guidelines for animal experiment.2.3. Cell culture
Human PTC cell TPC-1, K1 and normal thyroid cells Nthy-ori 3-
1 cells were cultured in Dulbecco's Modiﬁed Eagle medium
(DMEM) supplemented with 10% FBS. The cells were cultured in a
humidiﬁed incubator supplemented with 5% CO2.2.4. Transfection of miR-375 mimic
MiR-375 mimics (mimic-miR375) and control mimics (mimic-
control) were purchased from Invitrogen. Human PTC Cells were
cultured in DMEM (10% FBS). Twenty-four hours later, cells were
transfected with miR375 mimic or control by using Lipofectamine
2000 (Invitrogen) in antibiotic-free Opti-MEM medium (Gibco)
according to the manufacturer's instruction. The concentration of
miR375 mimic or control was 10 nM (ﬁnal concentration). The
culture medium was replaced with DMEM (10% FBS) 6 h after the
transfection.2.5. MiR-375 expression detection
Total RNA was extracted from human PTC tissues or PTC cells
using TRIzol reagent (Invitrogen) as described by the manufac-
turer. Then the RNA was reverse transcribed using a TaqMan
miRNA Reverse Transcription kit (Applied Biosystems) with a
miRNA-speciﬁc looped RT primer. The quantitative real-time PCR
for miR-375 was performed using TaqMan Universal PCR Master
Mix (Applied Biosystems) with miRNA-speciﬁc TaqMan minor
groove binder probes (Applied Biosystems). RNA U6 (Applied
Biosystems) was used as an internal control. All qRT-PCR studies
were performed in triplicate and the data were presented as
mean ± SD.2.6. Cell proliferation assay
Cell proliferation assay was performed by the CCK8 assay as
described in the manufacturer. First human PTC mock TPC-1, K1
cells or TPC-1, K1 cells with transfection were seeded into 96-well
plates (5000 cells/well). 2 h before the designed time point, CCK8
reagent was added to these wells (1:10), then incubate the cells for
another 2 h at 37 C. The absorbance (OD450) was expressed as
the proliferation of the cells. All the cell proliferation studies were
performed in triplicate, and the data were presented as
mean ± SD.
2.7. Colony formation assay
Approximately 500 mock TPC-1, K1 or transfected cells were
placed in a fresh 6-well plate for 12 h and cultured in DMEM me-
dium for another 2 weeks. Colonies were ﬁxed with methanol and
stained with 0.1% crystal violet in 20% methanol for 15 min. Then
the number of colonies was counted. All the colony formulation
studies were performed in triplicate and the data are presented as
mean ± SD.
2.8. Apoptosis assay
The human PTC mock TPC-1, K1 cells or TPC-1, K1 cells with
transfection were cultured for 48 h and harvested. Cells were
washed with PBS and stained with Annexin V and Propidium io-
dide. Then perform the apoptosis assay with an Annexin V-FITC
apoptosis detection kit by using a ﬂow cytometry (BD Biosciences)
equipped with CellQuest software (BD Biosciences). The tests
were performed in triplicate, and the data were presented as
mean ± SD.
2.9. Luciferase assay
The full length of the 30-UTR from ERBB2 was cloned into the
downstream region of the ﬁreﬂy luciferase gene using the pGL3-
control vector. Mutant ERBB2 was used as corresponding con-
trols. MiR-375 inhibitor and control were purchased from Invi-
trogen. The wild-type or mutant ERBB2 report vectors were co-
transfected with the miR375 mimic or inhibitor into TPC-1 cells
by Lipofectamine 2000. Cells were cultured in a humidiﬁed incu-
bator supplemented with 5% CO2. 48 h later, the cells were har-
vested for luciferase assay. Dual-Luciferase Assay was performed by
using the dual-luciferase reporter assay kit (Promega). The relative
luciferase activity was normalized with renilla luciferase activity.
The tests were performed in triplicate, and the data were presented
as mean ± SD.
2.10. Real-time PCR to detect the mRNA of ERBB2
The mRNA level of ERBB2 was detected by real time PCR. Total
RNAwas isolated from treated human PTC cells using TRIzol reagent
(Invitrogen). cDNA was synthesized from 10 mg total RNA using a
Reverse Transcription kit (Applied Biosystems). Taq man Real time
PCR was performed as follow programs, 95 C for 10 min, annealing
at required temperature for each primer for 15 s, and 72 C for 30 s,
for 40 cycles. The primers used were listed below. ERBB2, F:
-AGCCTTGCCCCATCAACTG-, R: -AATGCCAACCACCGCAGA-, probe:
eCCACTCCTGTGTGGACCTGGATGACA-; b-actin, F: -ATCTGGCACCA
CACCTTCTACAAT-, R: -CCGTCACCGGAGTCCATCA-, probe: -TGACC
CAGATCATGTTTGAGACCTTCAACAC. Probes were labeled with ﬂuo-
rescent reporter dyes FAM (ERBB2) or VIC (Actin). Actin was used as
an internal control. All qRT-PCRs were performed in triplicate and
the data were presented as mean ± SD.
Fig. 1. qRT-PCR analysis of miR-375 in human PTC tissues and cell lines. (A) Analysis of
miR-375 expression in human PTC tissues. Data are presented as fold-changes in hu-
man PTC tissues relative to normal tissues. (B) Analysis of miR-375 expression human
PTC cell lines (K1, TPC-1) compared with the normal thyroid gland cell line (Nthy-ori3-
1). All experiments were performed in triplicate and the data were presented as
mean ± SD, ***p < 0.001.
Fig. 2. qRT-PCR analysis of miR-375 expression in mock PTC cells or PTC cells trans-
fected with mimic-miR375 or mimic-control. All experiments were performed in
triplicate and the data were presented as mean ± SD. ***p < 0.001.
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Protein extract from transfected PTC cells were separated in a
10% SDS-polyacrylamide gel (Invitrogen) and electrophoretically
transferred onto a PVDFmembrane (GE). Membranes were blocked
and incubated for 2 hwith primer antibody ERBB2 and GAPDH (Cell
Signaling Technology). After washing with TBST for 3 times, the
membranes were incubated with horseradish peroxidase-linked
antibody for 1 h. The membranes were washed and the proteins
were visualized using ECL chemiluminescence and exposed to x-
ray ﬁlm. All of the samples were performed in triplicate.
2.12. Experimental metastasis assay in vivo
To investigate the effect of miR-375 on human PTC cell migra-
tion and invasion in vivo, mock TPC-1 cells, mimic-miR375 trans-
fected TPC-1 cells and mimic-control transfected TPC-1 cells were
injected into the left ventricle of BALB/c nude mice (3,000,000 cells
in 0.2 ml normal saline) by using a 26-gauge needle, as previously
described (11e13). Successful left ventricle injectionwasmonitored
by the pulsatile ﬂow of red blood into the needle hub indicating
correct placement. There were 8 mice in one group. 4 weeks later,
mice were sacriﬁced, thyroid glands were harvested and the
number of metastatic tumor nodules in each thyroid gland was
counted. The data were presented as mean ± SEM.
2.13. Statistical analysis
The data were expressed as the mean ± SEM or mean ± SD.
Statistical analysis was performed by t-test using SPSS 13.0 to
evaluate the signiﬁcance of differences between groups.
3. Results
3.1. MiR-375 level in human PTC tissues and cell lines
Previous studies indicated that miR-375 was abnormally
expressed in many types of human cancer, and they were involved
in the proliferation, apoptosis and development of human cancer
(14e16). In this studywe ﬁrst examine the expression of miR-375 in
PTC tissues. 60 pairs of PTC and noncancerous normal tissue sam-
ples were submitted to qRT-PCR assay. RNAs extracted form PTC
tissues were reverse transcript, the level of miR-375 was detected
by qPCR. U6 was used as the internal control. The results indicated
that themiR-375 gene expression in human PTC patient tissues was
signiﬁcantly decreased compared to normal tissues (p < 0.01)
(Fig. 1A). Next we try to test the level of miR-375 in human PTC cell
lines. The level of miR-375 in human PTC cells (TPC-1 and K1) and
normal thyroid cells Nthy-ori 3-1 were tested by qRT-PCR. The re-
sults indicated that the levels of miR-375 in TPC-1 and K1 cells were
also signiﬁcant down-regulated compared with the level in Nthy-
ori 3-1 cells (p < 0.01) (Fig. 1B). These results indicate that dereg-
ulation of miR-375 may play important roles in the PTC progression
and development.
3.2. Manipulation of miR-375 expression in PTC cells
To selectively regulate the expression level of miR-375 in human
PTC cells, miR-375 mimic transfection assay was performed. TPC-1
and K1 cells were transfected with mimic-miR375 or mimic-
control and cultured. The level of miR-375 in the treated cells
was tested by qRT-PCR. After the transfection of mimic-miR375, the
expression of miR-375 increased signiﬁcantly compare to mock
cells, while the level of miR-375 was not changed in the cells
transfected with mimic-control (p < 0.01) (Fig. 2). In order toinvestigate the biological effect of miR-375 in human PTC cells, we
manipulated the level of miR-375 by mimic transfection assay in
the followed study.
3.3. Up-regulation of miR-375 decrease human PTC cell
proliferation
The effect of miR-375 on human PTC cell proliferation was
examined by CCK8 assay. TPC-1 and K1 cells transfected with miR-
Fig. 3. Effect of miR-375 on PTC cell proliferation. (A) Mock K1 cells or K1 transfected
with mimic-miR375 or mimic-control cells were seeded into 96-well plates. CCK8
assay was performed to determine the cell proliferation. (B) Mock TPC-1 cells or TPC-1
transfected with mimic-miR375 or mimic-control cells were seeded into 96-well
plates. CCK8 assay was performed to determine the cell proliferation. (C) Colony-
forming growth assays were performed to determine the proliferation of PTC cells.
The colonies were counted. All experiments were performed in triplicate and the data
were presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
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were tested by CCK8. The results indicated that up-regulation of
miR-375 signiﬁcantly decreased the proliferation of TPC-1 and K1
cells compared with mock cells. The cells transfected with mimic-
control shows no changes (p < 0.01) (Fig. 3A and B). To further
conﬁrm the effect of miR-375 on human PTC cell proliferation,
colony-forming growth assay was performed. The results of colony-
formation assays demonstrated that clonogenic survival was
decreased after the transfectedwith mimc-miR375 in TPC-1 and K1
cells compared with mock cells, while there was no effect in the
cells transfected with mimic-control (p < 0.01) (Fig. 3C). Taken
together, these results indicated that induce the expression of miR-
375 in human PTC cells could induce growth inhibition in TPC-1
and K1 cells.
3.4. Up-regulation of miR-375 increase the apoptosis of human PTC
cell
Previous studies indicated that cell apoptosis may contribute to
the cell growth inhibition (17). To study whether the growth in-
hibition of human PTC cell was caused by the induction of cell
apoptosis, we performed Flow-cytometric analysis of TPC-1 and K1
cells with the transfection with mimic-miR375 or mimic-control.
The apoptotic rate of TPC-1 mimic-miR375 cells was about 5.8%
and the rate of K1 mimic-miR375 cells was about 6.4% while the
rate were 0.7% or 0.5% in mock TPC-1 or K1 cells. The results indi-
cated that the apoptotic rate of PTC cells transfected with mimic-
miR375 was signiﬁcantly increased than the rate of mock PTC
cells, while the rate in TPC-1 (0.8%) and K1 (0.6%) cells transfected
with mimic-control was no affected (p < 0.01) (Fig. 4). Therefore
over-expression of miR-375 could induce the apoptosis of human
PTC cell TPC-1 and K1.
3.5. ERBB2 is a direct target of miR-375
To investigate the mechanism of miR-375 on human PTC cells,
we searched the potential target genes by using commonly cited
programs (TargetScan, PicTar and miRanda). The predicted results
indicated that ERBB2 was a direct target of miR-375(Fig. 5A). In
order to validate whether ERBB2 is the right target gene of miR-
375, human PTC TPC-1 cells were co-transfected with pGL3-
ERBB2 and mimic-miR375/miR-375 inhibitor, then the dual
luciferase assay was performed. The luciferase results indicated
that overexpression of miR-375 in TPC-1 cells co-transfected with
ERBB2 WT led to a reduction of luciferase, while there was no
reduction of luciferase in the TPC-1 cells co-transfected with
ERBB2 Mut. When co-transfected miR-375 inhibitor with ERBB2
WT in TPC-1 cells led to luciferase increase (Fig. 5B). These results
indicated that ERBB2 was the direct target of miR-375. Further
study indicated that while transfected the PTC cells (K1 and TPC-
1) with mimic-miR375 or mimic-control, the both mRNA and
protein level of ERBB2 in mimic-miR375 group was decreased
signiﬁcantly compared to mimic-control (Fig. 5C and D). Consis-
tently, induction of microRNA-375 led to a decreased expression
of ERBB2 in human PTC cells.
3.6. Up-regulation of miR-375 suppresses the migration and
invasion of human PTC cell in vivo
To investigate the biological effect of miR-375 on human PTC cell
in vivo, human PTC TPC-1 mock cells, TPC-1 cells transfected with
mimic-miR375 or mimic-control were injected into nude mice via
tail vein. Four weeks later, mice were sacriﬁced, tissues were har-
vest and the number of metastatic nodules was counted. In TPC-1
mock group and the mimic-control group, there were some largetumor clusters; while no large tumor was found in the mimic-
miR375 group. The tumor number results indicated that trans-
fected with miR-375 signiﬁcantly decrease the migration and in-
vasion of human PTC cell in vivo (Fig. 6).4. Discussion
MiRs are a class of non-coding endogenous RNAs in plants and
animals. They were about 22 nucleotides in length and played
important roles in the transcriptional regulation of gene
Fig. 4. Effect of miR-375 on PTC cell apoptosis. Flow cytometry analysis of apoptosis in K1 and TPC-1 cells transfected with mimic-miR375 or mimic-control. All experiments were
performed in triplicate and the data were presented as mean ± SD. ***p < 0.001.
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in plants, animals and virus (18). There were contributed to inhi-
bition of translation or the degradation of mRNAs, then regulation
of target gene expression (19). Previous studies indicated that
miRNAs could act as oncogenes or tumor suppressor genes in the
processes of tumorigenesis (20e23). A few abnormal expressed
miRs were identiﬁed in human PTC; they played important roles in
the processed of human PTC (9). MiR-375 was identiﬁed on human
chromosome 2, it was ﬁrst found in the pancreas and it was be-
tween CRYBA2 and CCDC108 (24, 25). However the roles of miR-
375 in human PTC were not fully understood.
In this study we try to investigate the biological effect of miR-
375 in human PTC cells. In our work, we found miR-375 wasdown-regulated in human PTC tissues, further study indicated the
level of miR-375 was also down-regulated in human PTC cell lines.
In this study we transfected the PTC cells with mimic-miR375 to
up-regulate the expression of miR-375, the qRT-PCR study
conﬁrmed the expression of miR-375 was increased while trans-
fected with mimic-miR375. Thenwe studied the biological effect of
miR-375 on the human PTC cell lines, we found that over-
expression of miR-375 expression would inhibit the proliferation
of human PTC cell lines by the induction of cell apoptosis. Animal
study indicated that transfected with mimic-miR375 signiﬁcantly
decrease the migration and invasion of human PTC cell in vivo.
These results exhibit induction of miR-375 in human PTC cells
could inhibit the process of human PTC.
Fig. 5. ERBB2 is a direct target gene of miR-375. (A) Prediction of miR-375 binding sites in the 30UTRs of human ERBB2 genes. (B) Conﬁrm ERBB2 is the direct target gene of miR-375.
Cells were co-transfected with wild type or mutant ERBB2 and mimic-miR375, miR375 inhibitor or control, the dual-luciferase assay was performed. (C) ERBB2 mRNA expression
level was decreased by the transfection of mimic-miR375, as detected by qRT-PCR analysis. (D) ERBB2 protein expression level was decreased by the transfection of mimic-miR375,
as detected by Western blot analysis. All experiments were performed in triplicate and the data were presented as mean ± SD. ***p < 0.001.
X.-Z. Wang et al. / Journal of Pharmacological Sciences 130 (2016) 78e84 83ERBB2 is a member of EGFR family; it is associated in many
cancers, it could induce the proliferation of cancer cells (26). It
was overexpressed in many cancer patients (27). ERBB2 was
associated with Ras-MAPK and PI3K-Akt pathway, overexpression
of ERBB2 could increase cell proliferation and decrease cellFig. 6. Effects of miR-375 on the migration and invasion of PTC cells in vivo. The mock
and transfected cells were injected intravenously via tail vein respectively. 28 days
later, mice were sacriﬁced and the relative metastatic nodules were calculated. All
experiments were performed in triplicate and the data were presented as mean ± SEM.
***p < 0.001.apoptosis, high ERBB2 expression would deactivate the sensi-
tivity of cells to the chemotherapy and radiotherapy. In this study
we found that ERBB2 is a target of miR-375 by using commonly
cited programs, and dual luciferase assay results conﬁrmed that
ERBB2 is a direct target of miR-375. Further studies showed that
induction of miR-375 could decrease the expression of ERBB2 in
human PTC cells. But how did miR-375 inhibit PTC cell prolifer-
ation and induce apoptosis, whether the apoptosis was associated
with Ras-MAPK or PI3K-Akt path way was still unknown. To
better understand the action mechanism of miR-375, further
studies are needed.
In conclude, the present study indicated that miR-375 was
down-regulated in human PTC tissues and cell lines. Over-
expression of miR-375 could decrease the PTC cell proliferation,
induce PTC cell apoptosis and inhibit the migration and invasion
in vivo. Besides, we demonstrated themiR-375 regulate the PTC cell
behavior through directly targeting ERBB2, an inverse relationship
between miR-375 and ERBB2. These suggested that appropriate
application of miR-375 regulation might be a new sight for human
PTC treatment in the future.Conﬂict of interest
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